In a series of transactions disclosed through recent SEC filings, Martin Roper, Chief Executive Officer of Vita Coco Company, Inc. (NASDAQ: COCO), sold 50,000 shares of common stock. The total value of these sales is estimated at approximately $2.5 million. These transactions took place over two days, specifically on April 24 and April 27, 2026.
The details of the sale indicate that Mr. Roper sold 25,000 shares on April 24 and another 25,000 shares on April 27. Each of these transactions was conducted at a price of $50.00 per share. These disposals were carried out under the framework of a Rule 10b5-1 trading plan.
Immediately preceding the sale of these common shares, Mr. Roper engaged in the acquisition of stock through the exercise of options. On both April 24 and April 27, he exercised options to acquire 25,000 shares per day. These acquisitions were made at an exercise price of $10.178 per share, resulting in a total cost of approximately $508,900 for the 50,000 shares obtained.
Following the completion of these trades, Mr. Roper’s direct holdings in Vita Coco common stock stand at 298,484 shares. This activity comes as the company prepares to report its next quarterly earnings on April 29, 2026. The filing also provides a detailed breakdown of indirect holdings associated with Mr. Roper, including 215,631 shares held by the Christopher G. Roper Exempt Family Trust, 216,131 shares held by the Peter S. Roper Exempt Family Trust, and 216,131 shares held by the Thomas L. Roper Exempt Family Trust. Additionally, his spouse holds 41,200 shares.
The SEC filing further outlines an extensive portfolio of derivative securities held by the CEO in the form of non-qualified stock options. These include:
- Options to purchase 400,214 shares at $10.178, expiring in September 2029 (fully vested).
- Options to purchase 40,950 shares at $10.178, expiring in January 2031 (fully vested).
- 298,507 shares at an exercise price of $15.00, with annual vesting starting in November 2022 and expiration in October 2031.
- 46,875 shares at $16.91, with vesting beginning in March 2024 and expiration in March 2033.
- 185,133 shares at $16.91, which are fully vested and expire in March 2033.
- 62,743 shares at $26.18, with vesting beginning in March 2025 and expiration in March 2034.
- 70,715 shares at $32.78, with vesting beginning in March 2026 and expiration in March 2035.
Market Context and Analyst Perspectives
The stock of Vita Coco has experienced a notable upward trend, rising 71% over the past year. Despite this growth, some analysis suggests that the equity may currently be overvalued relative to its calculated fair value. However, recent institutional commentary provides a nuanced view of the company's trajectory.
Evercore ISI recently reiterated an Outperform rating for Vita Coco and increased its price target to $70. This move was supported by data showing a 51.1% rise in scanner data sales as of March 8, a trend linked to favorable promotional timing and improvements in product mix and pricing. Furthermore, Evercore ISI indicated that political developments have not negatively influenced the company's outlook regarding freight. Following discussions with management, the firm expressed optimism concerning long-term prospects and fiscal year 2026.
In a similar vein, Morgan Stanley adjusted its price target for the company to $57 while maintaining an Equalweight rating. This change followed an upward revision of their adjusted EBITDA estimates for fiscal years 2026 and 2027 by 11% and 12%, respectively. These revised estimates were based on the company's fourth-quarter performance and a modified enterprise value to EBITDA ratio projected for 2027.